NASDAQ:THRX Theseus Pharmaceuticals (THRX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.06▼$4.0650-Day Range$4.06▼$4.0752-Week Range$2.05▼$12.37VolumeN/AAverage Volume592,167 shsMarket Capitalization$179.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Theseus Pharmaceuticals alerts: Email Address Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Theseus Pharmaceuticals Stock (NASDAQ:THRX)Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.Read More Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. THRX Stock News HeadlinesAugust 9, 2024 | bloomberg.comThe True Cost of LayoffsMay 20, 2024 | bbc.co.ukKS2 / KS3 English: A Midsummer Night's Dream. 1: Welcome to AthensSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. February 14, 2024 | finance.yahoo.comTheseus Pharmaceuticals Announces Closing of Tender OfferFebruary 14, 2024 | prnewswire.comTheseus Pharmaceuticals Announces Closing of Tender OfferJanuary 30, 2024 | finance.yahoo.comConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsJanuary 20, 2024 | stockhouse.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, THRX, GRCL, ROVRDecember 31, 2023 | businesswire.comTHESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. December 29, 2023 | finance.yahoo.comIs Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?December 27, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX, CONNDecember 22, 2023 | marketwatch.comTheseus Pharmaceuticals Shares Rise 9.3% on Deal to Be Acquired by ConcentraDecember 22, 2023 | marketwatch.comConcentra Biosciences to Acquire Theseus Pharmaceuticals for $3.90 to $4.05/ShrDecember 22, 2023 | markets.businessinsider.comTheseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In CashDecember 22, 2023 | tmcnet.comTHRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to ShareholdersDecember 22, 2023 | finance.yahoo.comTheseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightNovember 27, 2023 | msn.comUP Fintech, Cerence, Irsa Inversiones Y Representaciones among premarket gainers packNovember 27, 2023 | markets.businessinsider.comTheseus Pharma To Evaluate Expression Of Interest From Foresite, OrbiM And Proposal From ConcentraSee More Headlines Receive THRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:THRX CUSIPN/A CIK1745020 Webtheseusrx.com Phone857-400-9491FaxN/AEmployees38Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.84% Return on Assets-23.64% Debt Debt-to-Equity RatioN/A Current Ratio29.93 Quick Ratio29.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.36 per share Price / Book0.76Miscellaneous Outstanding Shares44,230,000Free Float23,575,000Market Cap$179.57 million OptionableOptionable Beta3.98 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Iain D. Dukes DPHIL (Age 66)M.A., Co-Founder & Chairman Comp: $67.28kMr. Bradford D. Dahms (Age 36)President, CFO & Director Comp: $480.95kMs. Kristine Callahan CPAVP & ControllerKey CompetitorsActuate TherapeuticsNASDAQ:ACTUVeruNASDAQ:VERUKinnate BiopharmaNASDAQ:KNTEMarinus PharmaceuticalsNASDAQ:MRNSOyster Point PharmaNASDAQ:OYSTView All Competitors THRX Stock Analysis - Frequently Asked Questions How were Theseus Pharmaceuticals' earnings last quarter? Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) announced its quarterly earnings results on Monday, November, 15th. The company reported ($5.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $4.93. When did Theseus Pharmaceuticals' stock split? Theseus Pharmaceuticals shares reverse split before market open on Saturday, January 1st 2000. The 117.85-146 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 3rd 2014. An investor that had 100 shares of stock prior to the reverse split would have 81 shares after the split. When did Theseus Pharmaceuticals IPO? Theseus Pharmaceuticals (THRX) raised $150 million in an initial public offering (IPO) on Thursday, October 7th 2021. The company issued 10,000,200 shares at a price of $14.00-$16.00 per share. This page (NASDAQ:THRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theseus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theseus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THRX Stock Alerts